glaucoma

Microstent approval makes big news in glaucoma world
Microstent approval makes big news in glaucoma worldClinicians will soon have another treatment option for their patients with non-severe primary open-angle glaucoma (POAG). A micro invasive glaucoma surgical (MIGS) device (CyPass Micro-Stent, Alcon) has been approved by the FDA for use in patients with mild-moderate PAOG in conjunction with cataract surgery.
ABiC targets all sites of outflow resistanceAb-interno canaloplasty (ABiC) is a minimally invasive glaucoma surgery that accesses, catheterizes, and viscodilates all sites controlling aqueous outflow. When performed alone for uncontrolled glaucoma or with cataract surgery, it can result in reduced IOP and daily medication at follow-up through 12 months.
Glaucoma may not be the disease you think it is
Glaucoma may not be the disease you think it isClinicians continue to explore the relationship between IOP and cerebrospinal fluid pressure in glaucoma.
Aqueous drainage tube provides trabeculectomy-like efficacyIn a study including 23 eyes with a transscleral micro-lumen aqueous drainage tube after failing maximum tolerated medication, reductions in the mean IOP were observed as well as in the mean number of medications per day.
Multiple next-generation stents lead to better IOP controlThe use of multiple second-generation stent systems led to a 20% or higher reduction in IOP in a group of patients with mild-to-moderate, open-angle glaucoma.
Cyclophotocoagulation shows safety in glaucoma case seriesCharles L. Harris, MD, reviews safety and efficacy rates in a glaucoma case series after adding a proprietary laser system with probe to the surgical armamentarium.
CO2 laser-assisted procedure showing long-term efficacy, safety
CO2 laser-assisted procedure showing long-term efficacy, safetyCO2 laser-assisted sclerectomy performed with a proprietary laser system is a simplified filtration procedure that is showing good IOP-lowering efficacy and safety in eyes followed to 5 years.
Second pivotal trial confirms IOP-lowering efficacy of first-in-class agentResults from a second pivotal trial investigating latanoprostene bunod 0.024% (LBN) are consistent with another identically designed study showing that not only is LBN non-inferior to timolol maleate 0.5% for lowering IOP, but it has significantly greater efficacy.
Novel gelatin stent works effectively as stand-alone procedureOne-year results are reviewed for use of a novel ab-interno gelatin stent as a stand-alone procedure for patients with mild-to-moderate primary open-angle glaucoma.
New dual blade can help surgeons lower IOPA new trabecular meshwork excision blade takes a new approach in IOP reduction.